July 27, 2020
Daiichi Sankyo said on July 22 that it has struck a research collaboration accord with France’s Gustave Roussy for the development of its lead DXd antibody drug conjugates (ADCs) DS-1062 and patritumab deruxtecan (U3-1402) in lung and breast cancer. DS-1062,...read more